ADALIMUMAB (HUMIRA®) INHIBITS RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS (RA) PATIENTS WITH LONG-STANDING DISEASE: DATA AT TWO YEARS

被引：0
|
作者：
Keystone, E. [1 ]
Kavanaugh, A. [2 ]
Sharp, J. [3 ]
Spencer-Green, G. [4 ]
Segurado, O. G. [5 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Univ Calif San Diego, Ctr Innovat Therapy, San Diego, CA USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Abbott Labs, Parsippany, NJ USA
[5] Abbott Labs, Chicago, IL USA
来源：
RHEUMATOLOGY | 2004年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of adalimumab (Humira™) in the treatment of US patients with rheumatoid arthritis (RA)
    Bansback, N
    Brennan, A
    Sengupta, N
    VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [22] Adalimumab (HUMIRA®) monotherapy significantly improves fatigue in patients with severe rheumatoid arthritis (RA)
    Dietz, BM
    Sterz, R
    Holtbrügge, W
    Kupper, H
    Van de Putte, LBA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - +
  • [23] SUSTAINED EFFICACY OF ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE (MTX) IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Schiff, M. H.
    Weisman, M.
    Furst, D. E.
    Kavanaugh, A.
    Spencer-Green, G.
    Segurado, O. G.
    RHEUMATOLOGY, 2004, 43 : 40 - 40
  • [24] Impact of Adalimumab Therapy On Laboratory Parameters of Interest in Patients with Early or Long-Standing Rheumatoid Arthritis
    Furst, De
    Lacerda, Ana P.
    Andhivarothai, Nupun
    Kalabic, Jasmina
    Mozaffarian, Neelufar
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S211 - S212
  • [25] Association of clinical response and radiographic progression in early Rheumatoid Arthritis (RA):: Subanalysis of the premier study of adalimumab (HUMIRA®) plus MTX or MTX alone
    Genovese, M. C.
    Kavanaugh, A. F.
    Cohen, S. B.
    Emery, P.
    Sasso, E. H.
    Spencer-Green, G. T.
    RHEUMATOLOGY, 2006, 45 : I42 - I42
  • [26] Improvement in HAQ disability in rheumatoid arthritis (RA) with adalimumab (HUMIRA™) based on duration of disease.
    Emery, P
    Fleischmann, R
    Strand, V
    Reiss, WG
    Fischkoff, SA
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S313 - S313
  • [27] Adalimumab (HUMIRA®) monotherapy significantly improves health utility in patients with severe rheumatoid arthritis (RA)
    Dietz, BM
    Sterz, R
    Holtbrügge, W
    Kupper, H
    Van de Putte, LBA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - 392
  • [28] Cost effectiveness of adalimumab (HUMIRA™, Abbott) in the treatment of patients with moderate to severe rheumatoid arthritis (RA)
    Bansback, NJ
    Brennan, A
    Sengupta, N
    Chang, KY
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S215 - S215
  • [29] Effect of adalimumab (humira®) on response to influenza virus and pneumococcal vaccines in patients with rheumatoid arthritis (RA)
    Kaine, J.
    Kivitz, A.
    Birbara, C.
    Luo, A. Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 304 - 304
  • [30] Rates of serious infections from adalimumab (HUMIRA®) clinical trials of patients with Rheumatoid Arthritis (RA)
    Kent, J. D.
    Pangan, A. L.
    Spencer-Green, G. T.
    Szczerbak, N.
    Sasso, E. H.
    RHEUMATOLOGY, 2006, 45 : I42 - I43
12345